Annals of Oncology 14:1751-1757, 2003
© 2003 European Society for Medical Oncology
Original Paper |
Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma
1 Hôpital Henri Mondor, Gastroentérologie, Créteil, Val de Marne; 2 Hôpital Hotel Dieu, Gastroentérologie, Paris, Seine; 3 Hôpital Henri Mondor, Informatique Médicale, Créteil, Val de Marne; 4 Hôpital Henri Mondor, Hématologie Clinique, Créteil, Val de Marne; 5 Hôpital Hotel Dieu, Hématologie Clinique, Paris, Seine; 6 Hôpital Ambroise Paré, Informatique Médicale, Paris, Seine; 7 Hôpital Lariboisière, Anatomopathologie, Paris, Seine; 8 Hôpital Paul Brousse, Anatomopathologie, Villejuif, Val de Marne; 9 Groupe d’Étude des Lymphomes Agressifs (GELA); 10 Groupe d’Étude des Lymphomes Digestifs (GELD), France
Received 8 April 2003; revised 2 July 2003; accepted 12 August 2003
Background:
The usefulness of chemotherapy to treat gastric diffuse large B-cell lymphomas (DLBCL) is well known. Whether or not chemotherapy should be performed as the only treatment or after surgical resection is debated. The aim of this study was to compare two strategies: surgical resection plus chemotherapy versus chemotherapy alone.
Patients and methods:
Between January 1988 and December 1996, 58 patients included in the trials promoted by the Groupe d’Étude des Lymphomes de l’Adulte (GELA) (LNH-87 and LNH-93) received chemotherapy and 48 included in the protocol of the Groupe d’Étude des Lymphomes Digestifs (GELD) underwent surgical resection followed by chemotherapy. They all presented with localized DLBCL (stage IE and IIE according to the Ann Arbor classification). From the GELA group, seven patients received additional radiotherapy. Gastrectomy was total in 27 of the 48 patients in the GELD group. In both groups chemotherapy included anthracyclin and alkylating agents. Chemotherapy was more intensive in the GELA group than in the GELD group.
Results:
In the GELA and the GELD groups, distribution according to sex ratio, age (>60 or 
60 years), ECOG performance status (
2 or <2) and staging (IE or IIE) was similar. Univariate analysis comparing prognostic factors in both groups showed significant differences: serum lactate dehydrogenase level above normal (28.6% versus 2.4%, P = 0.001), tumor size >10 cm (28.6% versus 12.5%, P = 0.04), patients with International Prognostic Index (IPI) >1 (21.4% versus 11.1%, P = 0.168) and 5-year survival (79% versus 90%, P = 0.03). Multivariate analysis of prognostic factors with a Cox model showed that IPI was the only independent prognostic factor (odds ratio 3, P = 0.03). Consequently, patients with IPI 0–1 were selected for comparison between the GELA group (44 patients) and the GELD group (40 patients). There was no significant difference between the two groups. Median follow-up was 59 months (range 3–128). Estimates of 5-year survival rates and event-free survival rates were 90.5% versus 91.1% (P = 0.303) and 85.9% versus 91.6% (P = 0.187), respectively. In the GELA group, seven of 44 patients died: five from a lymphoma-unrelated cause and two from tumor progression. In the GELD group, four of 40 patients died: two of unrelated causes and two from tumor progression.
Conclusions:
This study shows that in localized gastric DLBCL with IPI 0–1, a similar 5-year survival rate (>90%) is to be expected with either surgery plus chemotherapy or chemotherapy alone.
Key words: chemotherapy, large B-cell lymphoma, stomach, surgery, treatment
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Wohrer, M. Troch, and M. Raderer Treatment of Localized Primary Gastric Lymphoma J. Clin. Oncol., June 10, 2006; 24(17): 2682 - 2682. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wohrer, A. Puspok, J. Drach, M. Hejna, A. Chott, and M. Raderer Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma Ann. Onc., July 1, 2004; 15(7): 1086 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ibrahim and A. Ezzat Failure of the International Prognostic Index to prognosticate outcome in primary gastric DLBC lymphoma Ann. Onc., May 1, 2004; 15(5): 841 - 841. [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Delchier Reply to Letter to the Editor on "Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma", by M. Binn, A. Ruskone-Fourmestraux, E. Lepage et al. (Ann Oncol 2003; 14: 1751-1757) Ann. Onc., May 1, 2004; 15(5): 842 - 842. [Full Text] [PDF]
|
|
|
|
|
|
H. Abali and I. Barista Comments on "Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma" by M. Binn, A. Ruskone-Fourmestraux, E. Lepage et al. (Ann Oncol 2003; 14: 1751-1757) Ann. Onc., May 1, 2004; 15(5): 841 - 842. [Full Text] [PDF]
|
|